ALX Oncology (ALXO) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 10, 2026, with shareholders able to vote online or by proxy.

• Three proposals are up for vote: election of three Class III directors, advisory approval of executive compensation, and ratification of KPMG LLP as auditor.

• The board recommends voting in favor of all proposals.

• Shareholders of record as of April 15, 2026, are entitled to vote; 134,559,917 shares are outstanding.

Voting matters and shareholder proposals

• Proposal 1: Elect Daniel Curran, Rekha Hemrajani, and Chris Takimoto as Class III directors for terms ending 2029.

• Proposal 2: Advisory vote on executive compensation (say-on-pay); prior year approval was 68.64%.

• Proposal 3: Ratification of KPMG LLP as independent auditor for fiscal year 2026.

• Shareholders may submit proposals for the 2027 meeting by December 21, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• The board consists of seven members, five of whom are independent.

• Directors are divided into three classes with staggered three-year terms.

• Board committees include audit, compensation, and corporate governance/nominating, all composed of independent directors.

• Board leadership is separated between the Chairman and CEO roles.

• The board emphasizes diversity and regular evaluation of director candidates.